Nuvation Bio (NUVB) Operating Expenses (2020 - 2026)

Nuvation Bio (NUVB) has reported Operating Expenses for 7 consecutive years, with $79.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 27.8% year-over-year to $79.3 million; the TTM figure through Mar 2026 stood at $295.3 million (down 54.03% YoY), while the FY2025 annual figure was $276.0 million, down 54.04% from the prior year.
• Operating Expenses retreated to $79.3 million in Q1 2026 per NUVB's latest filing, from $83.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $470.5 million in Q2 2024 and bottomed at $20.2 million in Q1 2024.
• Historically, Operating Expenses has averaged $69.3 million across 5 years, with a median of $37.9 million in 2022.
• Annual changes were most pronounced in 2024 — Operating Expenses jumped 1700.44% — and 2025, when it tumbled 86.0%.
• Nuvation Bio's Operating Expenses stood at $24.3 million in 2022, then dropped by 14.4% to $20.8 million in 2023, then jumped by 200.11% to $62.5 million in 2024, then jumped by 34.24% to $83.9 million in 2025, then dropped by 5.45% to $79.3 million in 2026.
• Business Quant data shows NUVB's Operating Expenses at $79.3 million in Q1 2026, $83.9 million in Q4 2025, and $66.2 million in Q3 2025.